Purpose: Paclitaxel and gemcitabine possess broad spectra of clinical activity, distinct mechanisms of cytotoxicity, and are differentially affected by mutations in cell-cycle regulatory proteins, such as bcl-2. This phase I trial was designed to identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of paclitaxel and gemcitabine when both drugs were given together on a once-every-two-week schedule in patients with solid tumors.
Introduction
Gemcitabine (2',2'-difluorodeoxycytidine; Gemzar®, Eli Lilly and Co., Indianapolis, IN) is a novel pyrimidine nucleoside analog with a broad spectrum of clinical activity and a relatively mild toxicity profile [1] [2] [3] . It is successively phosphorylated within the cell and incorporated into DNA as gemcitabine triphosphate, resulting in termination of DNA polymerization one nucleotide beyond the site of incorporation [3] . In clinical studies, gemcitabine has exhibited single agent activity against pancreas, lung (small-cell and non-small-cell), bladder, breast, head and neck and ovarian cancers [reviewed in 4, 5] .
There is a great deal of interest in the evaluation of gemcitabine in combination with other chemotherapeutic agents, especially those with distinct mechanisms of action, differing mechanisms of resistance and non-overlapping patterns of toxicity. Several preclinical studies have suggested promising combination activity between gemcitabine and other agents, including cisplatin and paclitaxel [6, 7] . The gemcitabine-cisplatin combination has been studied extensively and, in phase II clinical trials, has resulted in response rates of 32%~54% in patients with advanced non-small-cell lung cancer [4, 5] . Less data is available on the gemcitabine-paclitaxel combination. Using a panel of small cell lung cancer cell lines with differing mechanisms of resistance, Jensen et al demonstrated a very high level of collateral sensitivity between gemcitabine and paclitaxel, suggesting that mechanisms of resistance that affect one drug do not have a significant affect upon the other [8] . Further support of this is provided by Gazitt et al., who demonstrated that bcl-2 overexpression in myeloma cell lines conferred resistance to paclitaxel, but not gemcitabine [9] . Evidence for preclinical synergy between paclitaxel and another pyrimidine nucleoside analog, ara-C, has been demonstrated in hematologic neoplasms [10] . These observations support the clinical evaluation of the paclitaxel + gemcitabine combination.
Most of the clinical experience with paclitaxel has been with a once-every-three-week drug administration schedule while the majority of clinical experience with gemcitabine has been with a schedule that administers the drug on a weekly basis three out of every four weeks [4, 5, 11] . Differences in the frequency of drug administration and treatment cycle length pose a logistical problem for the development of this drug combination. Fortunately, phase I data exist for each drug using an everyother-week administration schedule. In a phase I study of gemcitabine, the maximum tolerated dose (MTD) was 3000 mg/m 2 [12] . Another trial using this same schedule reported an MTD of 4560 mg/m 2 [13] . Paclitaxel, infused over three hours, has been administered on an every-two-week schedule in doses up to 100 mg/m 2 with cisplatin without the routine use of hematopoietic growth factors [14, 15] . The feasibility of a biweekly dosing schedule for each drug prompted us to select this schedule for phase I evaluation.
The objectives of this study were 1) to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of paclitaxel and gemcitabine when administered to patients with advanced solid tumors on a onceevery-two-week schedule; 2) to determine the qualitative and quantitative toxicities of this drug regimen; and 3) to describe any antitumor activity. toxicity occurring at any point in the treatment cycle. Likewise, the criteria for dose-limiting toxicity were based on the maximum severity and duration of the toxicity occurring at any point in the treatment cycle. The paclitaxel dose was reduced by one dose level for grade 2 neutropenia or thrombocytopenia and the doses of both gemcitabine and paclitaxel were reduced by one dose level for grade 3 or 4 neutropenia or thrombocytopenia occurring just prior to the next scheduled treatment cycle. Gemcitabine dose was reduced for grade 2 or greater transaminase elevation or grade 3 or greater skin rash while paclitaxel dose was reduced for grade 3 or greater myalgias or arthralgias. Doses of both drugs were reduced for grade 3 or greater elevation in bilirubin. The DLT was defined as first-cycle loxicity consisting of WHO grade 4 neutropenia or thrombocytopenia lasting for > 5 days, febrile neutropenia (grade 2 or greater fever occurring in the setting of grade 4 neutropenia), grade 3-4 non-hematologic toxicity (except nausea and vomiting), or inability to begin cycle 2 within two weeks of the scheduled start date due to drug-related toxicity and delayed normal tissue recovery. The maximum tolerated dose (MTD) was defined as one dose level below that which induced DLT in at least two of three or two of six patients during the first cycle of therapy. Since doses of each drug could, be modified or delayed for moderate toxicities, the actual dosages and intervals of treatment were used to calculate the delivered dose intensity over the first three cycles of treatment. The dose administered of each drug (mg/m 2 ) was divided by the interval between treatment and the initiation of the next cycle and expressed as a fraction of the scheduled two-week interval. The delivered dose intensity was averaged over the first three cycles of treatment and expressed as mg/m 2 /two weeks.
Patients and methods

Patient eligibility
Patients with histologically or cytologically confirmed solid tumors refractory to conventional therapy were enrolled in the study. Eligibility criteria included the following: (1) age ^18 years; (2) estimated life expectancy > 12 weeks; (3) Zubrod performance status of 0-2; (4) no surgery, radiation or chemotherapy within four weeks prior to enrollment; (S) no prior paclitaxel or gemcitabine therapy; (6) adequate hematopoietic reserve (absolute neutrophil count (ANC) > 1500/ul and platelet count 2= 100,000/ul); (7) adequate hepatic and renal function (normal serum creatinine and bilirubin, serum aspartate aminotransferase (AST) < 3 times upper limit of normal); (8) normal prothrombin time (PT) and activated partial thromboplastin time (aPTT); and (9) presence of bidimensionally measurable and/or evaluable disease. All patients with central nervous system (CNS) metastases and medical conditions that were deemed incompatible with safe participation in the trial were excluded. All patients were required to provide informed consent according to federal and local Institutional Review Board guidelines.
Dosage and dose escalation
The starting dose level in this trial was paclitaxel 75 mg/m 2 administered intravenously (i.v.) over three hours followed by gemcitabine 1500 mg/m 2 i.v. over 30-60 minutes. Treatment was administered on an outpatient basis on day 1 of each two-week cycle. For each successive dose level, the dose of one drug was escalated while the other was held constant. At least three patients were treated at each dose level and no intra-patient dose escalation was permitted. Up to a two-week delay was permitted to allow blood counts to return to < grade I toxicity levels (i.e., neutrophils > 1500/ul and platelets > 75,000/ul). Since transient and asymptomatic myeolosuppression was an expected toxicity of this regimen, dose adjustments were not based on nadir values but rather on hematologic parameters obtained in preparation for the scheduled day of therapy. Dose adjustments for non-hematologic toxicity, however, were based on the maximum severity of the 
Pretreatment and follow-up evaluations
Pre-treatment evaluation included a complete history and physical examination, complete blood count (CBC) with leukocyte differential, prothrombin time (PT), activated partial thromboplastin time (aPTT), serum chemistries [bilirubin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine, uric acid, phosphorus, calcium, glucose, total protein, albumin, and electrolytes], urinalysis, and an electrocardiogram (ECG). During therapy, physical examination, toxicity assessment and CBC with leukocyte differential were obtained weekly or more frequently, if clinically indicated. CBC was obtained every-other-day in patients experiencing grade 4 neutropenia. In addition to these tests, serum chemistries and urinalysis were performed every two weeks, prior to initiation of a new cycle of therapy. Tumor reassessment was performed after the first three cycles of therapy (i.e., after week 6) and every eight weeks, thereafter. 
Results
Thirty-seven patients-received a total of 269 courses of treatment on the study. The patient characteristics are summarized in Table 1 . Thirty-three (89%) of 37 patients had received prior treatment. Most had received chemotherapy (31 of 37; 84%) and 16 of 37 patients (43%) had received prior radiation therapy. The median number of treatment cycles administered on this study was 6, which is equivalent to 12 weeks on therapy. The number of patients treated at each dose level are summarized in Table 2 . One patient entered on dose level 5 was inadvertently treated with paclitaxel 175 mg/m 2 rather than 125 mg/m 2 in the first cycle. That patient received subsequent cycles of treatment with paclitaxel 125 mg/m 2 + gemcitabine 2500 mg/m 2 (dose level 5).
Toxicity
Hematologic toxicity
The first course hematologic toxicity is summarized in Table 3 . Grade 4 neutropenia occurred in two of six patients treated on dose level 9 and was dose-limiting (i.e., lasted for ^5 days) in one patient. There were no episodes of febrile neutropenia observed during the first cycle of therapy. Overall, only five patients developed grade 4 neutropenia during the first cycle of therapy. Although the number of patients is small, several associations were identified between prior treatment and the occurrence of grade 4 neutropenia. These five patients had received a median of 2.5 different chemotherapy regimens prior to enrollment on this study. This compares to a median of one prior chemotherapy regimen received by the 32 patients who did not experience this toxicity. Of 16 patients who had received prior irradiation, four (25%) developed grade 4 neutropenia during cycle 1. In contrast, grade 4 neutropenia occurred in only one of 21 patients (5%) during cycle 1 who had not received prior radiation. Grade 4 thrombocytopenia lasting for 5 days occurred in one of six patients treated at dose level 3. This was not accompanied by any clinical evidence of bleeding.
Non-hematologic toxicities
No grade 4 non-hematologic toxicities were observed at any dose level during the first cycle of treatment. Grade 2-3 non-hematologic toxicities were infrequent and reversible. These toxicities consisted of elevations in serum transaminases (two episodes of grade 2 and one episode of grade 3), nausea or vomiting (four episodes of grade 2 and two episodes of grade 3), myalgias or arthralgias (four episodes of grade 2 and one episode of grade 3), and mucositis (one episode of grade 2 and one episode of grade 3). All of these toxicities were reversible. One of the six patients treated at dose level 9 experienced transient, but dose-limiting grade 3 elevation of ALT/SGPT. This elevation was asymptomatic and the patient went on to receive a total of seven cycles of therapy at reduced dosages.
Dose-limiting toxicity
As summarized above, DLT was achieved at dose level 9 (paclitaxel 175 mg/m 2 + gemcitabine 3500 mg/m 2 ) where one patient experienced dose-limiting neulropenia last- ing for > 5 days and one patient experienced grade 3 elevation in serum transaminase.
Maximum tolerated dose, recommended phase II dose, and dose-intensity analysis
As defined in the protocol, the maximum tolerated dose for this regimen is paclitaxel 150 mg/m 2 + gemcitabine 3500 mg/m 2 (dose level 8) which represents one dose level below that at which DLT was observed. We analyzed the delivered dose-intensity over the first three cycles of therapy to determine whether these doses could be administered repetitively. This analysis took into account both the dose reductions taken for each drug as well as any delays in drug administration. In this analysis, the actual doses of paclitaxel and gemcitabine delivered over the first three cycles were higher for dose level 7 than they were for dose level 8 (Table 4 ). This difference was due to the patients treated on dose level 8 requiring more frequent dose-reductions and dosedelays due to toxicity than those treated at dose level 7. Therefore, we consider dose level 7, paclitaxel 150 mg/m 2 administered intravenously over three hours followed by gemcitabine 3000 mg/m 2 administered intravenously over 30-60 minutes, as the recommended phase II doses.
Antitumor activity
Although not a primary endpoint of the study, antitumor activity was observed in several patients and is summarized in Table 5 . Four patients treated on this study had transitional cell carcinomas (three of the bladder, one of the renal pelvis). Two of these patients experienced objective partial responses (one lasting for 16 months and the other lasting for two months) while one patient had stable disease for four months. The patient with transitional cell carcinoma of the renal pelvis had unresectable disease at baseline and experienced an objective partial response within two months of beginning treatment. Overall, this patient achieved a 71% reduction in tumor size after 10 cycles (five months) of paclitaxel and gemcitabine. When maximal tumor response had been achieved, the patient underwent complete surgical resection of the residual mass (which still contained viable tumor cells). Three additional cycles of therapy were administered postoperatively as consolidation after which the patient remained clinically disease free for an additional six months. Five patients enrolled on this study had adenocarcinoma of unknown primary (ACUP). One patient with ACUP who had received two prior chemotherapy regimens (5-FU + leucovorin followed by cisplatin + etoposide) had a brief partial Abbreviations: TCC -transitional cell cancer; ACUP -adenocarcinoma of unknown primary; SCCHN -squamous cell cancer of head and neck; NSCLC -non-small-cell lung cancer. " Duration of response measured from the time of first determination of tumor shrinkage of > 50% to the time at which the tumor size had increased by >25% over smallest dimension. Duration of stable disease measured from the date of initiation of treatment to the date on which progressive disease was documented.
response to therapy lasting for 1.5 months. Another patient with ACUP who had received prior radiation therapy experienced a marked reduction in the number and intensity of extensive bone metastases beginning two months after initiation of paclitaxel + gemcitabine chemotherapy that lasted for 8+ months, at which time treatment was discontinued at the patient's request. Since bone-only disease is non-measurable, this patient was considered to have stable disease as his best response. Stable disease lasting from three to five months was observed in five other patients with a variety of other solid tumors.
Discussion
Paclitaxel and gemcitabine represent an attractive drug combination for clinical evaluation. Each drug is directed at a different cellular target: microtubules for paclitaxel and DNA for gemcitabine [1, 11] . The spectrum of clinical activity for each drug is broad and partially overlapping with paclitaxel active against ovary, breast, non-small-cell lung cancers, and transitional cell carcinoma of the bladder and gemcitabine active against pancreas and non-small-cell lung cancer, and transitional cell carcinoma of the bladder [4, 11] . There is also emerging evidence that cellular abnormalities associated with resistance to one drug may not confer resistance to the other. Gazitt et al. have demonstrated that bcl-2 overexpression confers resistance to paclitaxel, but not gemcitabine, in ARP-1 and 8226 myeloma cells [9] . Furthermore, simultaneous administration of gemcitabine and paclitaxel in this model was synergistic in vitro in clinically-achievable doses. For these reasons, we decided to evaluate this two-drug combination in a schedule that had been tested in phase I for each drug individually.
In this study, we demonstrate that paclitaxel and gemcitabine can safely be administered on the same day using a once-every-two-week schedule. Dose limiting toxicity was observed in two of six patients at dose level 9 (paclitaxel 175 mg/m 2 and gemcitabine 3500 mg/m 2 ). Although per protocol, this defined dose level 8 as the maximum-tolerated dose, an analysis of delivered doseintensity revealed that higher doses of both drugs could be administered over the first three cycles of therapy at dose level 7 than at dose level 8 (see Table 4 ). This was due to dose-reductions and dose-delays that were taken for toxicities that were moderate to severe, but not doselimiting. Therefore, dose level 7 (paclitaxel 175 mg/m 2 and gemcitabine 3000 mg/m 2 ) is recommended for further phase II evaluation.
Pharmacokinetic analysis was not performed in this trial. Therefore, no conclusions can be drawn regarding the possibility of a drug-drug interaction between paclitaxel and gemcitabine. We feel that it is unlikely that there was any adverse, clinically-significant interaction based on the following observations: 1) the spectrum of toxicity encountered in this trial was a combination of the toxcities described for each drug when used as single agents, 2) the severity of toxicities did not appear to be increased from what one would expect based on available data for each drug when used alone, and 3) an encouraging degree of antitumor activity was observed across a broad range of tumors. This question could be addressed in future trials. In addition to determining whether one drug had an impact on the metabolism or clearance of the other, such trials could help to elucidate the impact of dose and infusion duration on the intracellular pharmacology of gemcitabine.
Although not available at the time our study was initiated, preliminary data is available from several other trials using this same drug combination given on different administration schedules. Poole et al. reported on nine patients with recurrent epithelial ovarian treated with gemcitabine at a starting dose of 1000 mg/m 2 on days 1,8, and 15 and short-infusion paclitaxel 135 mg/m 2 on day 8 of a 28-day cycle [15] . Grade 4 hematologic toxicity (primarily thrombocytopenia on day 15) was reported in two of three patients during the first cycle of therapy at the initial dose level and suggested that the maximum tolerated dose would be approximately gemcitabine 800 mg/m 2 and paclitaxel 100 mg/m 2 . The substantial differences in myelotoxicity reported by Poole et al. compared to our own data suggest that high doses of gemcitabine and paclitaxel may not be easily tolerated using a weekly dosing schedule for gemcitabine with paclitaxel administered on day 8 without the support of hematologic growth factors. Despite this limitation, objective responses were reported in four of eight evaluable patients who had received prior platinum-based therapy. A phase II study of gemcitabine 900 mg/m 2 days 1 and 8 and paclitaxel 175 mg/m 2 over three hours on day 8, given every three weeks with granulocyte colony stimulating factor on days 9-15 was conducted in patients with stage IIIB or IV non-small-cell lung cancer who had received prior treatment with a cisplatin-or docetaxel-based regimen [16] . Two complete and five partial responses were reported in 24 patients evaluable for response (response rate: 29%). With the use of G-CSF, grade 3-4 neutropenia occurred in only two (8%) of 26 patients. Grade 2-3 neurotoxicity occurred in eight patients (31%), a problem not encountered in our trial. The fact that we were able to attain higher doses of gemcitabine without substantial hematologic toxicity and without the use of hematopoietic growth factors may have been due to the selection of a treatment schedule that permitted avoidance of dosing of either drug during periods of blood progenitor cell sensitivity.
In this study, objective responses were obtained in two patients with urothelial cancer and one patient with adenocarcinoma of unknown primary. In previously untreated patients with advanced transitional cell carcinoma, gemcitabine has been shown to have a 28%-38% response rate and paclitaxel a 42% overall response rate [17] [18] [19] . Thus, it is not surprising that good clinical activity was observed using this drug combination in patients with this malignancy. There is little data on the activity of new agents on adenocarcinomas of unknown primary. The observation of objective response in one and prolonged stabilization of disease in two other patients with this malignancy is provocative and suggests that this combination may be appropriate for further evaluation in patients with this disease. This combination may also be attractive for phase II evaluation in other malignancies, such as non-small-cell lung cancer, squamous cell cancer of head and neck, pancreatic cancer and ovarian cancer. Several such phase II trials are underway.
In conclusion, this trial demonstrates that paclitaxel and gemcitabine can be safely administered together on an every-two-week schedule. This schedule is associated with relatively mild toxicity and promising antitumor activity. The recommended phase II dose is paclitaxel 150 mg/m 2 over three hours followed by gemcitabine 3000 mg/m 2 over 30-60 minutes.
